Patients face wait for new cancer drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An estimated 3,500 post-menopausal Scottish women are now eligible for treatment with Arimidex after surgery, which reduces the risk of breast cancer returning.
The delay in approving the drug in England was criticised, with Pamela Goldberg, chief executive of Breast Cancer Campaign, describing it as a "country postcode lottery". Unlike Scotland, England has no fast-track process for approving new drugs and patients must wait for the National Institute for Clinical Excellence to complete its more detailed assessment.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments